As Congress considers reforms to private health insurance, we urge you to ensure that coverage provides meaningful access to the medications, services, and care patients need and protects them from practices that shift costs or create unnecessary barriers to treatment.
Letter to Congressman Craig Goldman supporting the Prior Authorization Accountability Act
We write to express our strong support for the Prior Authorization Accountability Act (H.R. 9396), which recently passed the Subcommittee on Health on a bipartisan basis. We thank you for your leadership in advancing meaningful transparency in the prior authorization process and urge Congress to swiftly pass this important legislation. For patients living with HIV, viral hepatitis, and other serious chronic conditions, prior authorization is too often an unnecessary barrier to timely, medically appropriate care. While our organization believes prior authorization should be significantly reduced across the healthcare system, greater transparency is an essential step toward accountability and reform.
Letter to House Ways and Means Committee supporting HR9504’s 340B transparency provisions
The 340B program is essential to HIV prevention and treatment. It was created to help safety-net providers, including HIV and STD clinics, stretch limited resources in order to serve more low-income and uninsured patients. We strongly support preserving the program so that care can be delivered to those who otherwise would be out of reach.
House testimony on FY27 funding for domestic HIV and hepatitis programs
The HIV+Hepatitis Policy Institute respectfully submits this testimony in support of increased funding for domestic HIV and hepatitis programs at the Department of Health and Human Services for FY 2027. Specifically, this testimony is in support of funding for the following initiatives, programs and divisions: Ending the HIV Epidemic Initiative – $395 million for the CDC Division of HIV/AIDS Prevention, $358.6 million for the HRSA Ryan White HIV/AIDS Program, $207.3 million for the HRSA Community Health Centers, and $52 million for the Indian Health Service; Ryan White HIV/AIDS Program – $3.13 billion; CDC Division of HIV Prevention – $822.7 million; CDC Division of Viral Hepatitis – $150 million; and the HHS Office of Infectious Disease and HIV/AIDS Policy – $7.6 million. We also support maintaining funding for CDC’s Eliminating Opioid-Related Infectious Diseases Program and Division of Adolescent and School Health; the Minority HIV/AIDS Initiative; AIDS Research at the NIH; the Title X Family Planning Program; the Teen Pregnancy Prevention Program; and the SAMHSA Hepatitis C Elimination Initiative Pilot.
23 patient groups letter to Senate Appropriations in support of additional FY26 hepatitis programs funding
We the undersigned 23 organizations urge you to protect and, if possible, increase funding for domestic viral hepatitis programs at the Centers for Disease Control and Prevention (CDC). At a time when we have tools including vaccines and curative treatments that can help eliminate viral hepatitis in the United States, we express our grave concern with the President’s FY 2026 budget request that eliminates $43 million in dedicated funding for hepatitis prevention. Instead, it proposes a $300 million block grant to states that would also include STD and tuberculosis prevention.